Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30837260 | 0.94 | KMT2A (0.63) | KMT2APARP10MAPTHPGDRAB9A | |
| SCHEMBL4105007 | 0.86 | GLA (0.61) | KMT2APARP10MAPTRAB9APOLB | |
| SCHEMBL8506170 | 0.85 | MAPT (0.59) | KMT2APARP10MAPTHPGDRAB9A | |
| SCHEMBL2517350 | 0.84 | KMT2A (0.73) | KMT2APARP10MAPTHPGDRAB9A | |
| SCHEMBL15763862 | 0.84 | KMT2A (0.56) | KMT2APARP10MAPTHPGDRAB9A | |
| SCHEMBL22505175 | 0.83 | MAPT (0.57) | KMT2APARP10MAPTHPGDRAB9A | |
| SCHEMBL4458942 | 0.83 | MAPT (0.57) | KMT2APARP10MAPTHPGDRAB9A | |
| SCHEMBL10656787 | 0.83 | HPGD (0.57) | KMT2APARP10MAPTHPGDRAB9A | |
| SCHEMBL6617827 | 0.83 | MAPT (0.61) | KMT2APARP10MAPTHPGDRAB9A | |
| SCHEMBL503642 | 0.83 | KMT2A (1.00) | KMT2APARP10MAPTHPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| EP-4457224-A1 | HETEROCYCLIC COMPOUNDS | BeiGene Switzerland GmbH (CH) | 2024-11-06 | — | — | EP | disclosed |
| US-20240327417-A1 | HETEROCYCLIC COMPOUNDS | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-03 | — | — | US | disclosed |
| WO-2024160276-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
| CN-118451073-A | Heterocyclic compounds | 百济神州有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230339854-A1 | Negative Allosteric Modulation of GluN3-Containing N-Methyl-D-Aspartate Receptors | UNIV EMORY (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339854-A1 | Negative Allosteric Modulation of GluN3-Containing N-Methyl-D-Aspartate Receptors | UNIV EMORY (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339854-A1 | Negative Allosteric Modulation of GluN3-Containing N-Methyl-D-Aspartate Receptors | UNIV EMORY (US) | 2023-10-26 | — | — | US | disclosed |
| EP-1453797-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY ENRICHED THIO COMPOUND | DSM IP Assets B.V. (NL) | 2004-09-08 | — | — | EP | disclosed |
| EP-1102757-B1 | SUBSTITUTED OXAZOLE AND THIAZOLE DERIVATIVES AS HPPAR GAMMA AND HPPAR ALPHA ACTIVATORS | GLAXO GROUP LTD (GB) | 2004-04-14 | — | — | EP | disclosed |
| EP-1181294-B1 | NOVEL DERIVATIVES AND ANALOGUES OF GALANTHAMIN | SANOCHEMIA PHARMAZEUTIKA AG (AT) | 2004-03-31 | — | — | EP | disclosed |
| US-20030199493-A1 | Novel derivatives and analogues of galanthamin | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2003-10-23 | — | — | US | disclosed |
| EP-1325908-A1 | Process for the preparation of an enantiomerically enriched thio compound | DSM N.V. (NL) | 2003-07-09 | — | — | EP | disclosed |
| WO-2003051827-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY ENRICHED THIO COMPOUND | DSM IP ASSETS B.V. (NL) | 2003-06-26 | — | — | WO | disclosed |
| US-6498174-B1 | AGONISTS TO PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; MODULATING BLOOD GLUCOSE AND LIPID LEVELS; REDUCING DYSLIPIDEMIA AND HYPERINSULINEMIA ASSOCIATED WITH IMPAIRED GLUCOSE TOLERANCE OR METABOLIC SYNDROME | SMITHKLINE BEECHAM CORPORATION | 2002-12-24 | — | — | US | disclosed |
| EP-1102757-A1 | SUBSTITUTED OXAZOLE AND THIAZOLE DERIVATIVES AS HPPAR GAMMA AND HPPAR ALPHA ACTIVATORS | GLAXO GROUP LIMITED (GB) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008002-A1 | SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS hPPAR GAMMA AND hPPAR ALPHA ACTIVATORS | GLAXO GROUP LIMITED (GB) | 2000-02-17 | — | — | WO | disclosed |
| US-4148809-A | Process for preparing dl-cis-1-hydroxy-3-substituted-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones | ELI LILLY AND COMPANY (US) | 1979-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327417-A1 | HETEROCYCLIC COMPOUNDS | NFATC1, CD4, ACIN1 | KMT2A 2438/4885PARP10 2675/4885MAPT 3912/4885 |
| US-20030199493-A1 | Novel derivatives and analogues of galanthamin | GALR1, GALNT1, GALK1 | KMT2A 3985/4885PARP10 741/4885MAPT 2569/4885 |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | KMT2A 2375/4885PARP10 2741/4885MAPT 4168/4885 |
| US-20230339854-A1 | Negative Allosteric Modulation of GluN3-Containing N-Methyl-D-Aspartate Receptors | GRIN3A, GRIN3B, GRIN1 | KMT2A 947/4885PARP10 2497/4885MAPT 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.